Predicting the prognosis in acute liver failure: results fron a retrospective pilot study using the LiMaX test Lock, et al. Nowadays, acute liver failure is a major cause of short mortality with a poor prognostic. Assessment of hepatic function is crucial in the follow-up of patients with fulminant liver failure. Breath testing has been used experimentally and clinically for several years; it is based on the principle that a measurable metabolite of an ingested substrate is expelled by the respiratory system. The ideal substrate would be metabolized solely by the liver and therefore selectively reflect liver metabolic function. To improve the diagnostic efficacy of these tests, several quantitative approaches have been proposed to measure metabolic liver function. The LiMaX test, a breath quantitative test that determines the absolute quantity of the cytochrome P450 1A2 (CYP1A2) system which is exclusively expressed in hepatocytes acinus and is proportional to parenchymal volume therefore that is not influenced by drugs or genetic variations.

Palabras clave:

2013-07-12   |   327 visitas   |   Evalua este artículo 0 valoraciones

Vol. 12 Núm.4. Julio-Agosto 2013 Pags. 524-526 Ann Hepatol 2013; 12(4)